The rapid advancements in stem cell technology have brought new solutions to human health. Theoretically, stem cells hold the potential to treat various refractory diseases, offering new hope for addressing major illnesses by repairing and replacing aged or damaged tissues. They show promise in multiple fields, including the nervous system, endocrine system, microvascular system, and immune system.

On the other hand, due to the late start of stem cell research in China, the market is mixed with good and bad players. There are many companies that use the concept of stem cells to "scare" people. In the field of health management, the situation is even more uneven, which makes people doubt the safety and reliability of stem cell technology.

“Although stem cells have become a major trend for the future, public misconceptions about them remain deeply entrenched: some believe they are panaceas, while others dismiss them as mere ‘myths.’ Meanwhile, the stem cell market is characterized by disorder, health management practices are highly varied and inconsistent, and people remain skeptical of technical services due to a lack of understanding,” said Han Zhihai, CEO of Sinocell.

Han Zhihai, CEO of Sinocell

Guided by this consideration, Beijing Health & Harmony Biotechnology Co., Ltd. (hereinafter referred to as “Health & Harmony”), founded in 2007, has carried out a parallel spin-off of its business divisions to focus on advancing the application of stem cells across various fields. This specifically includes areas primarily oriented toward cell storage and CDMO services.Han's Bio, focusing on the R&D of novel stem cell drugs and extracellular vesicle (exosome) productsHan's Pharmaceutical, Establishing various joint hospitals and physical examination centersHan's Medicine, and Shanghai Sinocell Life Health Technology Co., Ltd. (hereinafter referred to as “SinoShenzhou”）。

Headquarters Base of Sinohope Group Photo provided by the interviewee

After one year of development, Sinocell Group has emerged as a leading enterprise on par with Han’s United. Leveraging its technological foundations, including an innovative technology service platform and bioinformatics big data, Sinocell established two wholly-owned subsidiaries: Shanghai Han’s Ark Biotechnology Co., Ltd. (hereinafter referred to as “Han’s Ark”) and Beijing Sinocell Health Technology Promotion Co., Ltd. Together, these entities are committed to engineering, standardizing, and industrializing biotechnological processes, ultimately achieving large-scale industrial production and widespread application in the preventive healthcare and disease treatment sectors. The company’s current business portfolio spans beauty and wellness, bioinformatics big data, and life manufacturing facilities.

It is reported that Sinocell Group has established nearly 150 science popularization centers under the “Han’s Ark” brand, covering first-tier cities such as Beijing, Shanghai, and Hangzhou, as well as second- and third-tier cities including Guiyang and Qinghai.

In 1989, Han Zhongchao came to the Institute 150 of the French National Academy of Medicine to conduct postdoctoral research, thereby embarking on his career in regenerative medicine. Over the following three decades, Han Zhongchao published more than 500 papers, in《Lancet》《Nature Medicine》《Nature Communications》《Blood》Published over 300 SCI-indexed papers in journals (H-index: 58), granted more than 20 invention patents, and received 30 domestic science and technology awards.

Han Zhongchao, Academician of the French National Academy of Technologies; Foreign Corresponding Member of the French National Academy of Medicine

Academician Han Zhongchao is a Member of the French National Academy of Technologies and an International Corresponding Member of the French National Academy of Medicine. He serves as Director of the National Engineering Research Center for Stem Cell Technology, Director of the National Engineering Research Center for Cellular Products, and Chairman of the Academic Committee of the State Key Laboratory of Experimental Hematology.

In 2007, Academician Han Zhongchao embarked on the path of translating scientific research into practical applications by founding Hanyu United Group, with a commitment to making research benefits accessible to a broader population. Centered on cell therapy and regenerative medicine technologies, Hanyu United focuses on innovation and development within the cellular technology industry. According to QYResearch data, the compound annual growth rate (CAGR) of China’s stem cell medical industry market size was approximately 15% from 2020 to 2026. In the coming years, China’s share of the global stem cell medical industry market is expected to rise further.

Great Opportunities, Yet Five Major Challenges Remain in the Translational Research of Stem Cells. According to Academician Han Zhongchao, “First is ethics, which pertains to standards for stem cell preparation; for instance, the acquisition and use of embryonic stem cells must adhere to ethical principles. Second is technology; stem cell research started relatively late in China and requires highly sophisticated technical support, with many technical hurdles still awaiting resolution. Third is safety; since China began accepting applications for new stem cell drugs in 2017, insufficient real-world experimental data have been accumulated. Scientific evaluation and monitoring are needed for tumorigenicity, immunogenicity, and heterogeneity of cells. Fourth is legal and regulatory compliance; national and local laws and regulations must be followed, and supervision and management should be strengthened.”

“The final issue concerns marketization. If we can advance science popularization efforts to help the public understand what stem cells are, their applications, and how they are used, then any new breakthroughs in R&D will shorten the public’s acceptance period, enabling more people to benefit more quickly,” said Academician Han Zhongchao. Every emerging entity must follow the logic of development. Issues such as how to successfully translate scientific research outcomes into practical applications and how to promote and popularize them must be carefully considered. This is also a major reason why Han’s Group incubated Sinocelltech.

In recent years, health management services focusing on personalized health assessments, wellness consultations, and disease rehabilitation have gained significant momentum. The "Healthy China 2030" Planning Outline explicitly emphasizes the continuous advancement of national health information services that integrate prevention, treatment, rehabilitation, and self-management across the entire life cycle. With the deepening aging of society, rising incidence of chronic diseases, and growing public health awareness, coupled with the rapid emergence of new technologies such as artificial intelligence, big data, and biotechnology, the field of health management is experiencing an unprecedented opportunity for development.

According to the VCBeat database, there have been a total of 76 investment deals in the primary market for the health management sector from 2022 to present. Additionally, data from PwC indicates that China is the world’s second-largest healthcare industry market, with the broader health industry market size growing at a compound annual growth rate (CAGR) of up to 13% over the past few years.

Health management is relevant to everyone, yet the sector continues to face pain points such as the absence of industry standards, low public awareness, and an incomplete service chain, which hinder public access to and adoption of emerging technologies like stem cells. Therefore, in the view of Academician Han Zhongchao, having Sinocelltech enter the health management sector from a market-oriented perspective—continuously popularizing stem cell knowledge and developing applications—plays a significant role in promoting the establishment of industry standards for health management and expanding the use of stem cells to benefit a broader population.

By rapidly collecting and analyzing data, Sinocell Group continuously accelerates product upgrades and diversifies user experiences, helping to establish industry standards and ultimately optimizing and enhancing health management systems. Meanwhile, Sinocell Group leverages scenario-based customization to meet diverse needs, driving cell therapy services toward digitalization and automation.

Specifically, Sinocelltech has three major business segments, including Han’s Ark, SinoCell (which includes the imcell Health & Aesthetics Space and the Greater Health Industrial Park), and Cell Xumi.

Hans Ark integrates science popularization, skincare, health management, leisure, and appreciation. With a focus on human life and health, it has established a comprehensive industrial chain in the broader health sector, creating a highly customized, full-lifecycle health management platform that provides users with more systematic and convenient health management services.

Han’s Ark Innovative Technology Service Platform encompasses a Health Index Assessment Platform, Beauty and Wellness Technology Projects, and CDM Services for platform development. It also establishes “My Cell Center (MCC),” the “Life-GPS Precision Health Intervention System,” and the “IMCELL Health Aesthetics Space,” providing comprehensive health management across the entire life cycle.

“At present, Han’s Ark has established a presence in cities including Beijing, Shanghai, Hangzhou, Guiyang, and Qinghai. Currently, there are approximately 150 Han’s Ark Science Popularization Centers. Over the next three years, we will fully achieve a nationwide scale of 500 science popularization centers and health aesthetics spaces,” said Han Zhihai, CEO of Sinocell神州.

Xinuocell comprises the imcell Health & Aesthetics Space and the Greater Health Industrial Park. The concept of the Health & Aesthetics Space is forward-looking, marking a transition from product-oriented approaches to comprehensive health and lifestyle services. “Healthful Beauty” is not only a positive health paradigm but also represents a new awareness and methodology for future anti-aging interventions.

The Health Aesthetics Space leverages highly customized biological intervention technologies to develop anti-aging supportive intervention technologies and products, including IMCELL, biotech skincare products, Haixi Mistry, and oral health technology products.

The Grand Health Industrial Park, anchored in the bio-medical sector, is a high-quality, innovative, and specialized science and technology industrial park that integrates biopharmaceuticals, medical devices, pharmaceutical R&D, big health data, wellness and nursing care, technological exchange, urban medical technology, biopharmaceutical talent, intelligent manufacturing, and supporting services for the health industry. Phase I of the base project covers an area of 97 mu, with a total construction floor area of 140,000 square meters, and is positioned as a “regional landmark science and technology industrial park.”

Sumi Big Data is a health big data platform developed by Sinohope Group, based on data collected from platforms such as Sumi-ERP, Sumi-SaaS, and Sumi Health Management. This data is characterized by its large volume, diversity, authenticity and value, rapid processing speed, and long-term sustainability.

Leveraging the extensive big data collected from Xumi, Sinopharm is continuously accelerating product upgrades and optimization, with the potential to drive the establishment of industry standards.

Xinuo Shenzhou boasts leading R&D advantages and a comprehensive R&D and production platform, offering one-stop R&D and manufacturing services. Leveraging its Cell Valley ecosystem within an industrial cluster and a team of highly specialized R&D experts, the company provides enterprises with innovative process development and manufacturing solutions. By prioritizing high-value-added technology output over mere capacity provision, Xinuo Shenzhou’s offerings encompass CRO and CMO services for cell-based products, clinical research, and comprehensive solutions for establishing complete stem cell technology systems.

Currently, more than a dozen stem cell products have been successfully approved and launched globally. In contrast, the majority of such products in China remain in the research and development stage. From an application perspective, mesenchymal stem cells cover a broader range of indications; however, existing products are difficult to promote on a large scale due to high costs, challenges in achieving large-scale commercialization, and limited scope of application.

On the other hand, as an emerging industry, stem cells are heavily influenced by policy and, due to a relatively late start, lag significantly behind leading international research.

Whether in terms of research, promotion, or application, we still have a long way to go. Through SinoCellular, we can continue to conduct in-depth stem cell research while accelerating the translation of scientific achievements, enabling cutting-edge technologies to rapidly benefit a broader population.

The core team of Sinohope has been deeply engaged in the big health sector for decades, possessing expertise in health, medical care, and biotechnology, along with extensive experience in fostering market maturity. Mr. Han Zhihai, the General Manager, brings over ten years of experience in the life and health industry, having participated in numerous technological engineering developments and industrial commercialization projects, and holding multiple invention patents. Additionally, Dr. Wang Jialun, who holds a Ph.D. in Tumor Biology from Uppsala University in Sweden, serves as Chief Scientific Officer, while Raymond ASTRI, an international big data expert, serves as Chief Technology Officer.

“Enterprises in the stem cell field must further solidify basic research during the process of translating scientific achievements into practical applications. Key technologies cannot be acquired by asking, purchasing, or begging; therefore, it is imperative to strengthen basic research to foster disruptive innovations and overcome core technological bottlenecks, thereby enhancing the translation of achievements. Focusing on key core technologies within the field, we must devote ourselves wholeheartedly, unite our efforts, and persevere relentlessly to accelerate the translation of scientific achievements. Furthermore, we should strengthen the reserve of high-tech talent in the field, prioritize independent talent development, and cultivate highly skilled technical professionals and master craftsmen,” said Academician Han Zhongchao.

“Amid immense external pressure and a relatively chaotic market, we are in even greater need of like-minded partners to join us in facing a challenging future,” said Han Zhihai, CEO of Sinocell.

In the future, Sinocell Group will continue to optimize its strategic layout, ensure compliance across all business operations, launch the “Health Aesthetics Space” initiative, advance the development of an information technology platform, accelerate the industrialization of cell-based technologies, and empower the intelligent manufacturing of cell therapies.